COMPANY ANNOUNCEMENT NO.24/2010, November 30, 2010 At the annual general meeting of Chr. Hansen Holding A/S held on 30 November 2010, the following business was transacted: • Adoption of the annual report 2009/10 and discharge of the Board of Directors and the Management Board. • It was resolved to pay a dividend of DKK 0.64 per share of DKK 10. • It was resolved to remunerate board members with a basis fee of DKK 300,000. However, the chairman will receive 3 times the basis fee and the deputy chairman one 1½ times the basis fee. Furthermore, the committee positions will be remunerated with one third of the basis fee and the chairman of the audit board will be remunerated with one half of the basis fee. • Ole Andersen was re-elected Chairman of the Board of Directors. • Frédéric Stévénin, Gaëlle d'Engremont, Alice Dautry and Henrik Poulsen were re-elected to the Board of Directors. Mark Wilson was elected as new member of the Board of Direc-tors. • PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab was re-appointed as auditor of the company. • The Board of Directors was authorised to let the company purchase own shares, in the period ending on 29 November 2015, to an extent that the total shareholding of own shares in the company will not exceed 10 % of the share capital. The purchase price for the shares must not deviate more than 10 % from the price quoted at the time of the acquisi-tion for the company's shares on Nasdaq OMX Copenhagen A/S. • The chairman of the meeting, attorney-at-law Søren Meisling, was authorised to apply for registration of the resolutions passed and to make any such amendments thereto as may be required or requested by the Danish Commerce and Companies Agency as a condition for registration or approval. For further information, please contact: Ole Andersen, Chairman Tel: +45 4574 7109 Lars Frederiksen, CEO Tel: +45 4574 7474 Ulrik Soendergaard, Corporate Communications Tel: +45 4574 7109 About Chr. Hansen Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products are centered around cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2009/10 financial year was EUR 576 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Colors & Blends. It has more than 2,300 dedicated employees in over 30 countries. Chr. Hansen was founded in 1874 and is today listed on NASDAQ OMX Copenhagen. For further information, please visit www.chr-hansen.com.
Resolutions passed at the annual general meeting of Chr. Hansen Holding A/S
| Source: Chr. Hansen Holding A/S